Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (130) 130
Patent (32) 32
Publication (18) 18
Magazine Article (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (83) 83
humans (82) 82
oncology (71) 71
obstetrics & gynecology (65) 65
index medicus (62) 62
middle aged (56) 56
aged (54) 54
cancer (47) 47
adult (45) 45
ovarian cancer (44) 44
hematology, oncology and palliative medicine (42) 42
obstetrics and gynecology (35) 35
neoplasm staging (34) 34
carcinoma (32) 32
chemotherapy (31) 31
aged, 80 and over (30) 30
ovarian neoplasms - pathology (27) 27
chemistry (25) 25
ovarian neoplasms - drug therapy (25) 25
inorganic chemistry (24) 24
metallurgy (24) 24
basic electric elements (23) 23
compounds thereof (23) 23
electricity (23) 23
non-metallic elements (23) 23
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (23) 23
indexing scheme relating to structural and physical aspects ofsolid inorganic compounds (21) 21
performing operations (21) 21
transporting (21) 21
carcinoma, ovarian epithelial (20) 20
retrospective studies (18) 18
care and treatment (17) 17
manufacture or treatment of nanostructures (17) 17
measurement or analysis of nanostructures (17) 17
nanotechnology (17) 17
paclitaxel (17) 17
specific uses or applications of nanostructures (17) 17
surgery (17) 17
survival (17) 17
disease-free survival (16) 16
treatment outcome (16) 16
analysis (15) 15
article (15) 15
cisplatin (14) 14
gynecologic-oncology-group (14) 14
neoplasms, glandular and epithelial - pathology (14) 14
ovarian neoplasms - genetics (14) 14
radiology (14) 14
research (14) 14
oncology, experimental (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
carboplatin (12) 12
cisplatin - administration & dosage (12) 12
ovarian neoplasms - surgery (12) 12
paclitaxel - administration & dosage (12) 12
survival rate (12) 12
trial (12) 12
neoplasms, glandular and epithelial - drug therapy (11) 11
prognosis (11) 11
young adult (11) 11
cervical cancer (10) 10
phase-iii trial (10) 10
radiotherapy (10) 10
uterine cervix (10) 10
women (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
carboplatin - administration & dosage (9) 9
cohort studies (9) 9
health aspects (9) 9
ovarian neoplasms - metabolism (9) 9
tumors (9) 9
uterine cervical neoplasms - pathology (9) 9
hysterectomy (8) 8
neoplasm, residual (8) 8
nuclear radiation (8) 8
ovarian neoplasms - mortality (8) 8
radiation-therapy (8) 8
radiology, nuclear medicine & medical imaging (8) 8
survival analysis (8) 8
adenocarcinoma (7) 7
brachytherapy - methods (7) 7
drug resistance, neoplasm (7) 7
kaplan-meier estimate (7) 7
management (7) 7
neoplasms, glandular and epithelial - surgery (7) 7
patient outcomes (7) 7
ca-125 (6) 6
combined modality therapy (6) 6
comparative analysis (6) 6
concurrent chemotherapy (6) 6
diseases (6) 6
endocrine system diseases (6) 6
endometrial cancer (6) 6
epithelial ovarian (6) 6
follow-up studies (6) 6
medical colleges (6) 6
neoplasm recurrence, local - drug therapy (6) 6
neoplasms, glandular and epithelial - genetics (6) 6
patients (6) 6
proportional hazards models (6) 6
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (159) 159
French (11) 11
German (6) 6
Korean (2) 2
Spanish (2) 2
Chinese (1) 1
Indonesian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer
by Herzog, Thomas J., MD and Krivak, Thomas C., MD and Fader, Amanda Nickles, MD and Coleman, Robert L., MD
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2010, Volume 203, Issue 1, pp. 68.e1 - 68.e6
Objective We sought to determine the association between tumor responses in vitro to platinum therapy by using the ChemoFx drug response marker and overall... 
Obstetrics and Gynecology | platinum-based chemotherapy | chemotherapy drug response marker | ovarian cancer | in vitro chemosensitivity testing | DRUG | 1ST-LINE TREATMENT | CARBOPLATIN | ASSAY | PHASE-III | CHEMOTHERAPY | PACLITAXEL | OBSTETRICS & GYNECOLOGY | TRIAL | RESPONSES | CISPLATIN | Adenocarcinoma - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Proportional Hazards Models | Carboplatin - administration & dosage | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Cisplatin - pharmacology | Adenocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Carboplatin - pharmacology | Neoplasm Staging | Ovarian Neoplasms - drug therapy | Drug Screening Assays, Antitumor | Medical tests | Chemotherapy | Patient outcomes | Ovarian cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text National Cancer Data Base Analysis of Radiation Therapy Consolidation Modality for Cervical Cancer: The Impact of New Technological Advancements
by Gill, Beant S., MD and Lin, Jeff F., MD and Krivak, Thomas C., MD and Sukumvanich, Paniti, MD and Laskey, Robin A., MD and Ross, Malcolm S., MD and Lesnock, Jamie L., MD and Beriwal, Sushil, MD
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2014, Volume 90, Issue 5, pp. 1083 - 1090
Purpose To utilize the National Cancer Data Base to evaluate trends in brachytherapy and alternative radiation therapy utilization in the treatment of cervical... 
Radiology | Hematology, Oncology and Palliative Medicine | UNITED-STATES | UTERINE CERVIX | ONCOLOGY | CONCURRENT CHEMOTHERAPY | PATTERNS | RADIOTHERAPY PRACTICE | EXTERNAL-BEAM | BRACHYTHERAPY | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CARE | EPIDEMIOLOGY | Age Factors | United States | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Hispanic Americans - statistics & numerical data | Radiotherapy, Intensity-Modulated - utilization | Uterine Cervical Neoplasms - pathology | Carcinoma, Squamous Cell - radiotherapy | Radiosurgery - utilization | Socioeconomic Factors | Carcinoma, Squamous Cell - mortality | Brachytherapy - trends | Health Services Accessibility | Adult | Female | Retrospective Studies | Uterine Cervical Neoplasms - mortality | Radiotherapy, Intensity-Modulated - mortality | Brachytherapy - mortality | Radiotherapy Dosage | Continental Population Groups - classification | Uterine Cervical Neoplasms - radiotherapy | Cancer Care Facilities - supply & distribution | Databases, Factual - statistics & numerical data | Kaplan-Meier Estimate | Radiotherapy, Intensity-Modulated - trends | Radiosurgery - trends | Analysis of Variance | Survival Analysis | Aged | Brachytherapy - utilization | Radiosurgery - mortality | Continental Population Groups - statistics & numerical data | Databases | Radiotherapy | Analysis | Cervical cancer | MORTALITY | DIAGNOSIS | PATIENTS | NEOPLASMS | RADIOLOGY AND NUCLEAR MEDICINE | COMPARATIVE EVALUATIONS | HISTOLOGY | CHEMOTHERAPY | GYNECOLOGY | HAZARDS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: An analysis of GOG 182
by Horowitz, Neil S and Miller, Austin and Rungruang, Bunja and Richard, Scott D and Rodriguez, Noah and Bookman, Michael A and Hamilton, Chad A and Krivak, Thomas C and Maxwell, G. Larry
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 8, pp. 937 - 943
Purpose To examine the effects of disease burden, complex surgery, and residual disease (RD) status on progression-free (PFS) and overall survival (OS) in... 
SURVIVAL | TRIAL | CYTOREDUCTIVE SURGERY | GYNECOLOGIC-ONCOLOGY-GROUP | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | VOLUME | RESIDUAL DISEASE | CARCINOMA | PREDICTION | Multivariate Analysis | Prognosis | Humans | Middle Aged | Peritoneal Neoplasms - surgery | Kaplan-Meier Estimate | Gynecologic Surgical Procedures | Treatment Outcome | Neoplasm, Residual | Disease-Free Survival | Time Factors | Ovarian Neoplasms - therapy | Adult | Female | Aged | Peritoneal Neoplasms - therapy | Ovarian Neoplasms - surgery | Gync17 | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Proteomic analysis of ovarian cancer proximal fluids: Validation of elevated peroxiredoxin 1 in patient peripheral circulation
by Hoskins, Ebony R and Hood, Brian L and Sun, Mai and Krivak, Thomas C and Edwards, Robert P and Conrads, Thomas P
PLoS ONE, ISSN 1932-6203, 09/2011, Volume 6, Issue 9, p. e25056
Background: Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy in the United States. Unfortunately, a validated protein... 
OXIDATIVE STRESS | CARCINOGENESIS | PROTEIN | BIOLOGY | EXPRESSION | CARCINOMA | ABUNDANCE | RESOURCE | Humans | Middle Aged | Peroxiredoxins - metabolism | Neoplasms, Glandular and Epithelial - metabolism | Blotting, Western | Tandem Mass Spectrometry | Extracellular Fluid - metabolism | Carcinoma, Ovarian Epithelial | Chromatography, Liquid | Adult | Female | Aged | Ovarian Neoplasms - metabolism | Proteomics - methods | Proteins | Medical research | Biological products | Analysis | Medicine, Experimental | Liquid chromatography | Medical screening | Mass spectrometry | Enzyme-linked immunosorbent assay | Ovarian cancer | Peroxiredoxin | Oxidative stress | Ovarian carcinoma | Endometrial cancer | Oncology | Identification | Malignancy | Blood | Fluids | Surgery | Peripheral blood | Bioindicators | Peripheral circulation | Enzymes | Gel electrophoresis | Gynecology | Benign | Mass spectroscopy | Workflow | Breast cancer | Gene expression | Patients | Obstetrics | Esophagus | Medicine | Inflammatory bowel disease | Hospitals | Womens health | Medical prognosis | Proteomics | Biomarkers | Uterine cancer | Ascites | Prostate cancer | Immunoassays | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Re: Implications of upper abdominal disease in advanced ovarian cancer after surgical cytoreduction and relation with tumor biology
by Hamilton, Chad A and Krivak, Thomas C and Maxwell, G. Larry
Gynecologic Oncology, ISSN 0090-8258, 2011, Volume 123, Issue 3, pp. 616 - 616
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | SURVIVAL | IMPACT | ONCOLOGY | EPITHELIAL OVARIAN | OBSTETRICS & GYNECOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Corrigendum to ā€œDoes adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group studyā€ [Gynecol. Oncol. 151 (2018) 18ā€“23]
by Olawaiye, Alexander B and Java, James J and Krivak, Thomas C and Friedlander, Michael and Mutch, David G and Glaser, Gretchen and Geller, Melissa and O'Malley, David M and Wenham, Robert M and Lee, Roger B and Bodurka, Diane C and Herzog, Thomas J and Bookman, Michael A
Gynecologic Oncology, ISSN 0090-8258, 01/2019, Volume 152, Issue 1, pp. 220 - 220
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer
by Rutherford, Thomas and Orr, James and Grendys, Edward and Edwards, Robert and Krivak, Thomas C and Holloway, Robert and Moore, Richard G and Puls, Larry and Tillmanns, Todd and Schink, Julian C and Brower, Stacey L and Tian, Chunqiao and Herzog, Thomas J
Gynecologic Oncology, ISSN 0090-8258, 2013, Volume 131, Issue 2, pp. 362 - 367
Abstract Objective Use of in vitro chemoresponse assays for informing effective treatment selection is a compelling clinical question and a topic of debate... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Prospective clinical trial | Chemoresponse assay | Ovarian cancer | SURVIVAL | CHEMOSENSITIVITY | RESISTANCE ASSAY | BEVACIZUMAB | PERITONEAL | DRUG-RESISTANCE | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY | TRIAL | ONCOLOGY | PLATINUM RESISTANCE | EPITHELIAL OVARIAN | Prospective Studies | Double-Blind Method | Humans | Middle Aged | Drug Resistance, Neoplasm | Survival Rate | Treatment Outcome | Disease-Free Survival | Peritoneal Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Aged | Ovarian Neoplasms - drug therapy | Drug Screening Assays, Antitumor | Fallopian Tube Neoplasms - drug therapy | Medicine, Experimental | Medical research | Relapse | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older
by Rowland, Michelle R., MD, PhD and Lesnock, Jamie L., MD and Farris, Coreen, PhD and Kelley, Joseph L., MD and Krivak, Thomas C., MD
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2015, Volume 212, Issue 6, pp. 763.e1 - 763.e8
Objective Treatment for advanced-stage epithelial ovarian cancer (AEOC) includes primary debulking surgery (PDS) or neoadjuvant chemotherapy (NACT). A... 
Obstetrics and Gynecology | neoadjuvant chemotherapy | primary debulking surgery | cost comparisons | ovarian cancer | CYTOREDUCTIVE SURGERY | GYNECOLOGIC-ONCOLOGY-GROUP | IMPROVED SURVIVAL | ELDERLY-WOMEN | PACLITAXEL | OBSTETRICS & GYNECOLOGY | TRIAL | CISPLATIN | QUALITY-OF-LIFE | INTRAPERITONEAL | CARCINOMA | Neoplasms, Glandular and Epithelial - pathology | Cytoreduction Surgical Procedures - economics | Humans | Neoplasms, Glandular and Epithelial - therapy | Ovarian Neoplasms - pathology | Neoadjuvant Therapy - economics | Neoplasms, Glandular and Epithelial - economics | Ovarian Neoplasms - economics | Cost-Benefit Analysis | Carcinoma, Ovarian Epithelial | Ovarian Neoplasms - therapy | Female | Aged | Chemotherapy, Adjuvant - economics | Neoplasm Staging | Cancer patients | Comparative analysis | Adjuvant treatment | Ovarian cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Treatment Patterns and Outcomes in Pregnancy-Associated Adenocarcinoma of the Cervix
by Taylor, Sarah E and Smith, Ashlee L and Krivak, Thomas C and Rungruang, Bunja
Journal of Gynecologic Surgery, ISSN 1042-4067, 02/2014, Volume 30, Issue 1, pp. 5 - 11
Objective: Cervical cancer occurs in āˆ¼1/2200 pregnancies. Limited data exist for optimal management of cervical adenocarcinomas, which have seen a... 
Original Articles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer
by Dann, Rebecca Byler and DeLoia, Julie A and Timms, Kirsten M and Zorn, Kristin K and Potter, Jennifer and Flake, Darl D and Lanchbury, Jerry S and Krivak, Thomas C
Gynecologic Oncology, ISSN 0090-8258, 2012, Volume 125, Issue 3, pp. 677 - 682
Abstract Objective Our objective was to determine the rate of BRCA1/2 deficiency in platinum-sensitive and platinum-resistant tumors from a cohort of unselect... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA mutations | Ovarian cancer | SURVIVAL | FREQUENT | PROTEIN | POLYMERASE | SOMATIC MUTATIONS | PACLITAXEL | OBSTETRICS & GYNECOLOGY | PHASE-III TRIAL | INHIBITION | CISPLATIN | ONCOLOGY | BRCANESS | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasms, Glandular and Epithelial - metabolism | Drug Resistance, Neoplasm | BRCA2 Protein - biosynthesis | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Ovarian Neoplasms - metabolism | Genes, BRCA1 | BRCA1 Protein - deficiency | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Gene Expression | BRCA1 Protein - biosynthesis | BRCA1 Protein - genetics | Disease-Free Survival | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Aged | BRCA2 Protein - deficiency | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | BRCA2 Protein - genetics | Care and treatment | Chemotherapy | Genetic aspects | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study
by Olawaiye, Alexander B and Java, James J and Krivak, Thomas C and Friedlander, Michael and Mutch, David G and Glaser, Gretchen and Geller, Melissa and O'Malley, David M and Wenham, Robert M and Lee, Roger B and Bodurka, Diane C and Herzog, Thomas J and Bookman, Michael A
Gynecologic Oncology, ISSN 0090-8258, 10/2018, Volume 151, Issue 1, pp. 18 - 23
To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival... 
Progression | Chemotherapy | Dose modification | G-CSF | Ovarian cancer | Dose reduction | SURVIVAL | CARBOPLATIN | CYCLOPHOSPHAMIDE | DOXORUBICIN | RANDOMIZED-TRIAL | PACLITAXEL | OBSTETRICS & GYNECOLOGY | PHASE-III TRIAL | BREAST-CANCER | CISPLATIN | ONCOLOGY | CARCINOMA | Doxorubicin - therapeutic use | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Dose-Response Relationship, Drug | Ovary - surgery | Carboplatin - therapeutic use | Neoplasms, Glandular and Epithelial - mortality | Female | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Ovary - pathology | Kaplan-Meier Estimate | Neoplasms, Glandular and Epithelial - therapy | Treatment Outcome | Cytoreduction Surgical Procedures - methods | Granulocyte Colony-Stimulating Factor - therapeutic use | Paclitaxel - therapeutic use | Peritoneal Neoplasms - mortality | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Carcinoma, Ovarian Epithelial | Ovarian Neoplasms - therapy | Aged | Neoplasm Staging | Peritoneal Neoplasms - therapy | Women | Oncology, Experimental | Analysis | Patient outcomes | Adjuvant treatment | Research | Health aspects | Cancer | dose reduction | progression | dose modification | chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study
by Tian, Chunqiao and Ambrosone, Christine B and Darcy, Kathleen M and Krivak, Thomas C and Armstrong, Deborah K and Bookman, Michael A and Davis, Warren and Zhao, Hua and Moysich, Kirsten and Gallion, Holly and DeLoia, Julie A
Gynecologic Oncology, ISSN 0090-8258, 2011, Volume 124, Issue 3, pp. 575 - 581
Abstract Purpose Efflux transporters of the ATP-binding cassette (ABC) family are major determinants of chemoresistance in tumor cells. This study examined... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | ABCB1 | ABCC2 | Common variants | GOG | Advanced stage ovarian cancer | MULTIDRUG TRANSPORTER | RESISTANCE PROTEIN | PACLITAXEL RESISTANCE | DRUG-RESISTANCE | P-GLYCOPROTEIN | OBSTETRICS & GYNECOLOGY | CELL LUNG-CANCER | ONCOLOGY | MDR1 GENE | EXPRESSION | MRP2 ABCC2 | SINGLE NUCLEOTIDE POLYMORPHISMS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Deoxycytidine - administration & dosage | Humans | Middle Aged | Carboplatin - administration & dosage | Cisplatin - administration & dosage | Polymorphism, Genetic | Ovarian Neoplasms - genetics | Young Adult | ATP-Binding Cassette Transporters - genetics | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Topotecan - administration & dosage | Adult | Female | Multidrug Resistance-Associated Proteins - genetics | ATP Binding Cassette Transporter, Sub-Family B | Aged | Neoplasm Proteins - genetics | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Doxorubicin - administration & dosage | Women | Medical colleges | Chemotherapy | Patient outcomes | Genes | Oncology, Experimental | Genetic research | Genetic aspects | Research | Ovarian cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis
by Gill, Beant S and Bernard, Mark E and Lin, Jeff F and Balasubramani, Goundappa K and Rajagopalan, Malolan S and Sukumvanich, Paniti and Krivak, Thomas C and Olawaiye, Alexander B and Kelley, Joseph L and Beriwal, Sushil
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 3, pp. 365 - 372
Abstract Background For node-positive vulvar cancer, adjuvant radiotherapy has an established benefit, whereas the impact of chemotherapy is unknown. A... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Vulvar cancer | Chemotherapy | Adjuvant | Node positive | NCDB | GYNECOLOGIC-ONCOLOGY-GROUP | PROGNOSTIC-FACTORS | PHASE-II | CERVICAL-CANCER | OBSTETRICS & GYNECOLOGY | THERAPY | ONCOLOGY | PROPENSITY SCORE METHODS | CONCURRENT CHEMOTHERAPY | CISPLATIN CHEMOTHERAPY | SQUAMOUS-CELL CARCINOMA | CHEMORADIATION | Vulvar Neoplasms - surgery | Vulvar Neoplasms - radiotherapy | United States | Vulvar Neoplasms - drug therapy | Humans | Middle Aged | Lymphatic Metastasis | Chemoradiotherapy, Adjuvant | Young Adult | Vulvar Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Cohort Studies | Practice Guidelines as Topic | Databases | Analysis | Radiation | Adjuvant treatment | Cancer | Rankings | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Preoperative Intensity Modulated Radiation Therapy and Chemotherapy for Locally Advanced Vulvar Carcinoma: Analysis of Pattern of Relapse
by Beriwal, Sushil, MD and Shukla, Gaurav, PhD and Shinde, Ashwin, BS and Heron, Dwight E., MD, FACRO, FACR and Kelley, Joseph L., MD and Edwards, Robert P., MD and Sukumvanich, Paniti, MD and Richards, Scott, MD and Olawaiye, Alexander B., MD and Krivak, Thomas C., MD
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2013, Volume 85, Issue 5, pp. 1269 - 1274
Purpose To examine clinical outcomes and relapse patterns in locally advanced vulvar carcinoma treated using preoperative chemotherapy and intensity modulated... 
Radiology | Hematology, Oncology and Palliative Medicine | TRIAL | CISPLATIN | ONCOLOGY | CHEMORADIATION | PHASE-II | RADIOTHERAPY | CANCER | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Lymph Node Excision | Chemoradiotherapy - adverse effects | Inguinal Canal | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Carcinoma, Squamous Cell - surgery | Surgical Wound Infection - surgery | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Neoplasm, Residual | Vulvar Neoplasms - pathology | Vulvar Neoplasms - therapy | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Radiotherapy Dosage | Vulvar Neoplasms - surgery | Chemoradiotherapy - methods | Carcinoma, Squamous Cell - therapy | Treatment Outcome | Preoperative Care | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Radiotherapy, Intensity-Modulated | Chemotherapy | Relapse | Carcinoma | Nuclear radiation | Analysis | Radiotherapy | Cancer | Diseases | Index Medicus | SURGERY | PATIENTS | URACILS | LYMPH NODES | WOUNDS | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | TOXICITY | CHEMOTHERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study
by Rungruang, Bunja J and Miller, Austin and Krivak, Thomas C and Horowitz, Neil S and Rodriguez, Noah and Hamilton, Chad A and Backes, Floor J and Carson, Linda F and Friedlander, Michael and Mutch, David G and Goodheart, Michael J and Tewari, Krishnansu S and Wenham, Robert M and Bookman, Michael A and Maxwell, G. Larry and Richard, Scott D
Cancer, ISSN 0008-543X, 03/2017, Volume 123, Issue 6, pp. 985 - 993
BACKGROUND The purpose of this study was to determine the effect of retroperitoneal (RP) exploration on progressionā€free survival (PFS) and overall survival... 
surgical debulking | retroperitoneal exploration | disease burden | ovarian cancer | lymphadenectomy | SURVIVAL | METASTASIS | GOG 182 | PRIMARY CYTOREDUCTIVE SURGERY | NODE INVOLVEMENT | IMPACT | ONCOLOGY | DISEASE | CARCINOMA | Neoplasms, Glandular and Epithelial - pathology | Lymph Nodes - pathology | Humans | Middle Aged | Retroperitoneal Space - surgery | Ovarian Neoplasms - pathology | Treatment Outcome | Ovarian Neoplasms - mortality | Cytoreduction Surgical Procedures | Neoplasms, Glandular and Epithelial - surgery | Neoplasm Metastasis | Neoplasm Grading | Neoplasms, Glandular and Epithelial - mortality | Survival Analysis | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Adult | Female | Aged | Neoplasm Staging | Odds Ratio | Ovarian Neoplasms - surgery | Cancer survivors | Care and treatment | Breast cancer | Social aspects | Lymphatic system | Ovarian carcinoma | Exploration | Oncology | Patients | Survival | Optimization | Lymph nodes | Ovarian cancer | Surgery | Aorta | Hazard assessment | Cancer | Lymph
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights